Laminin Peptide (AHK)

Not FDA Approved✓ WADA Permitted

AHK peptide / Ala-His-Lys / Laminin-derived tripeptide

skin aesthetic◈Clinical EvidenceLaminin-derived tripeptide / Cell adhesion peptide

Tripeptide (Ala-His-Lys) derived from laminin, a key basement membrane protein. Promotes cell adhesion, migration, and wound healing. Stimulates collagen I and III synthesis, upregulates integrin expression. Used in cosmetic formulations and wound healing applications. Mimics laminin's cell-binding domain.

Confidence

55%

Half-Life ~hours

Cost ~$80/mo

Quick Reference

Routetopical / subcutaneous

MechanismMimics the cell-adhesion domain of laminin (α1 chain). Binds integrin receptors ...

SequenceAla-His-Lys

Mol. Weight354.39 Da

Reviewed2026-08-08

Mechanism of Action

Mimics the cell-adhesion domain of laminin (α1 chain). Binds integrin receptors (α2β1, α6β1) on keratinocytes and fibroblasts → promotes cell adhesion and migration. Upregulates collagen I/III, fibronectin, and integrin expression. Enhances wound healing via fibroblast activation. Promotes angiogenesis in wound bed.

Dosing Protocol

Topical: 100-500ppm in serum/cream, applied BID to face or wound area. SC: 100-200μg daily near wound site. Microneedling enhances absorption.

Key Studies

2015

GHK and related peptides in skin regeneration

PMID 26236730review

2011

Laminin-derived peptides in wound healing

PMID 21883646preclinical

2009

AHK peptide promotes collagen synthesis in fibroblasts

PMID 19152643in_vitro

Adverse Effects

Very well toleratedRare skin irritation (topical)No systemic effects reportedSafe for long-term use

Contraindications

Known hypersensitivity to peptide
Active skin infection at application site

Storage

Room temperature. Stable in cosmetic formulations. Protect from excessive heat and light.

Clinical Applications

["skin_quality"
"wound_healing"
"collagen_synthesis"
"anti_aging"]